The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|54|4|1483-1484

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.54, Iss.4, 2011-10, pp. : 1483-1484

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

PNPLA3 I148M variant is associated with metabolic stress‐response phenotype in patients with nonalcoholic fatty liver disease

By  

HEPATOLOGY, Vol. 61, Iss. 5, 2015-05 ,pp. : 1769-1769

John Wiley & Sons Inc

Access to resources Recommend Favorite

I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 12, 2015-12 ,pp. : 2537-2546

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patatin‐like phospholipase domain containing‐3 Ile148Met and fibrosis progression after liver transplantation

By  

HEPATOLOGY, Vol. 54, Iss. 4, 2011-10 ,pp. : 1484-1484

John Wiley & Sons Inc

Access to resources Recommend Favorite

Toll‐Like Receptor 3 and 7/8 Function Is Impaired in Hepatitis C Rapid Fibrosis Progression Post‐Liver Transplantation

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 13, Iss. 4, 2013-04 ,pp. : 943-953

John Wiley & Sons Inc

Access to resources Recommend Favorite

PNPLA3 as a liver steatosis risk factor following living‐donor liver transplantation for hepatitis C

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E335-E339

John Wiley & Sons Inc

Access to resources Recommend Favorite